Impact of obesity treatment on gastroesophageal reflux disease

World J Gastroenterol. 2016 Jan 28;22(4):1627-38. doi: 10.3748/wjg.v22.i4.1627.

Abstract

Gastroesophageal reflux disease (GERD) is a frequently encountered disorder. Obesity is an important risk factor for GERD, and there are several pathophysiologic mechanisms linking the two conditions. For obese patients with GERD, much of the treatment effort is focused on weight loss and its consistent benefit to symptoms, while there is a relative lack of evidence regarding outcomes after novel or even standard medical therapy is offered to this population. Physicians are hesitant to recommend operative anti-reflux therapy to obese patients due to the potentially higher risks and decreased efficacy, and these patients instead are often considered for bariatric surgery. Bariatric surgical approaches are broadening, and each technique has emerging evidence regarding its effect on both the risk and outcome of GERD. Furthermore, combined anti-reflux and bariatric options are now being offered to obese patients with GERD. However, currently Roux-en-Y gastric bypass remains the most effective surgical treatment option in this population, due to its consistent benefits in both weight loss and GERD itself. This article aims to review the impact of both conservative and aggressive approaches of obesity treatment on GERD.

Keywords: Fundoplication; Gastric banding; Gastric bypass; Gastroesophageal reflux disease; Obesity; Sleeve gastrectomy.

Publication types

  • Review

MeSH terms

  • Bariatric Surgery* / adverse effects
  • Gastroesophageal Reflux / diagnosis
  • Gastroesophageal Reflux / etiology
  • Gastroesophageal Reflux / physiopathology
  • Gastroesophageal Reflux / therapy*
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Obesity / complications
  • Obesity / diagnosis
  • Obesity / physiopathology
  • Obesity / therapy*
  • Patient Selection
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome
  • Weight Loss

Substances

  • Gastrointestinal Agents